JPRN-jRCTs031220666招募中3 期
JCOG2103: Randomized phase III study comparing systemic therapy and debulking surgery consisting of primary tumor resection with systemic therapy alone for clinical stage IVA (cT1-2bN0-1M1a) non-small cell lung cancer with radiologically undetermined pleural dissemination - DEBULK-LUNG
WATANABE Shun-ichi0 个研究点目标入组 170 人开始时间: 2023年2月28日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 79age old（—）
- 性别
- All
入选标准
- •Primary registration criteria
- •(1) Pathologically diagnosed as non-small cell lung cancer by any of the following
- •(i) Histological or cytological diagnosis of the primary tumor
- •(ii) Histological diagnosis of pleural disseminatio
- •(2) Histological diagnosis of pleural dissemination lesion by thoracoscopic or open chest biopsy (positive pleural fluid cytology alone is not acceptable).
- •(3) The patient has cT1a-2bN0-1M1a clinical stage IVA (UICC TNM classification, 8th edition) with all of the following criteria (i) to (viii) on chest contrast CT, thin slice CT, brain contrast CT or MRI, or PET/CT.
- •(i) No pleural dissemination lesion is detected on thin slice CT, or a pleural dissemination lesion is present but not measurable (maximum diameter less than 10 mm).
- •(ii) PET/CT shows no apparent abnormal accumulation of FDG in the pleura suspicious for pleural dissemination.
- •(iii) No additional tumor nodule in the contralateral lung.
- •(iv) No Grade 2 or higher pleural effusion
- •(v) No nodule suspected as pericardial dissemination in the pericardium.
- •(vi) No evidence of pericardial effusion exceeding physiological accumulation.
- •(vii) No cN1 lymph node lesion with extranodal infiltration
- •(viii) Primary tumor and N1 lymph node (in case of cN1) are considered completely resectable by partial resection, segmental resection, or lobectomy.
- •(4) confirmed EGFR gene mutations or ALK translocation status for non-squamous cell carcinoma.
- •(5) Over 18 years old and under 79 years old.
- •(6) Performance status 0 or1
- •(7) No prior thoracic surgery
- •(8) No history of chemotherapy for lung cancer
- •(9) No history of radiation therapy with mediastinum or hil um for other cancer types. No history of Grade 2 or higher radiation pneumonitis
- •(10) No complication of autoimmune disease or a history of chronic or recurrent autoimmune disease.
- •(11) No interstitial pneumonitis, pulmonary fibrosis, nor severe emphysema on chest CT.
- •(12) Predicted residual volume per second after resection is greater than 800 mL.
- •(13) Adequate function of major organs.
- •(14) Written informed consent.
- •Secondary registration selection criteria
- •(1) Primary registration was performed.
- •(Driver gene mutation positive) Three courses of standard of care drug therapy (SoC) was completed
- •(Driver gene mutation negative) Four courses of SoC was completed or only three courses is completed due to adverse events.
- •(2) Following (i)-(ii) is satisfied.
- •(i) Contrast-enhanced CT after last courses of SoC does not show obvious progressions compared to CT before primary registration.
- •(ii) No obvious progressions from the start of SoC .
- •(Driver gene mutation positive)
- •Within 56 days from the start of the final course of SoC.
- •(Driver gene mutation positive)
- •Within 48 days from the start of the final course of SoC.
- •(4) Secondary registration is within 14 days of the response evaluation
- •(5) Within 57-182 days from the primary registration.
- •(6) Primary tumor are considered completely resectable
- •(7) Predicted residual volume per second after resection is greater than 800 mL.
- •(8) Adequate function of major organs.
排除标准
- •(1) Simultaneous or metachronous (within 5 years) double cancers , with the exception of intramucosal tumor curable with local therapy.
- •(2) Active infection requiring systemic therapy.
- •(3) Fever over 38 degrees Celsius
- •(4) Female during pregnancy, within 28 days of postparturition, or during lactation. Male who wants partner's pregnancy.
- •(5) Psychological disorder difficult to participate in this clinical study.
- •(6) Receiving continuous systemic corticosteroid or immunosuppressant treatment.
- •(7) Uncontrollable diabetes mellitus.
- •(8) Uncontrollable hypertension.
- •(9) History of unstable angina pectoris within three weeks or myocardial infarction within six months before registration.
- •(10) Have an uncontrolled valvular disease, dilated cardiomyopathy, hypertrophic cardiomyopathy.
- •(11) Positive HBs antigen, HBC angigen or HIV antigen.
研究者
相似试验
招募中
3 期
JCOG1701: Randomized phase III study comparing cessation or continuation of PD-1 Pathway Blockade for patients with advanced non-small-cell lung cancerJPRN-jRCT1031190032OHE Yuichiro172
招募中
3 期
JCOG2107E: A randomized phase III trial comparing etoposide plus carboplatin combination therapy with/without durvalumab (MEDI4736) for advanced neuroendocrine carcinoma of the digestive systemneuroendocrine carcinoma of the digestive systemJPRN-jRCT2031230456Morizane Chigusa74
招募中
2 期
JCOG2203: A randomized controlled phase II/III trial of neoadjuvant chemotherapy for Japanese patients with esophagogastric junction adenocarcinomaJPRN-jRCTs031230182KUROKAWA Yukinori460
进行中（未招募）
3 期
JCOG1109: A randomized controlled phase III comparing CF versus DCF versus CF-RT as neoadjuvant treatment for locally advanced esophageal cancerclinical stage IB/II/III thoracic esophageal cancerJPRN-jRCTs031180202Kato Ken600
进行中（未招募）
3 期
JCOG1314: A randomized controlled phase III study comparing docetaxel, CDDP and 5-FU with CDDP and 5-FU in patients with metastatic or recurrent esophageal canceresophageal cancerJPRN-jRCTs031180143TSUBOSA Yasuhiro240